420 related articles for article (PubMed ID: 4039568)
21. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
Finotti P; Palatini P
J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
23. 5 alpha-Dihydro-11-deoxycorticosterone as a mineralocorticoid agonist and antagonist: evidence for a weak mineralocorticoid as an antagonist of potent mineralocorticoids.
Sekihara H; Yazaki Y
J Steroid Biochem Mol Biol; 1993 Apr; 45(4):235-8. PubMed ID: 8499332
[TBL] [Abstract][Full Text] [Related]
24. Spironolactone and canrenoate-K: relative potency at steady state.
Ramsay L; Asbury M; Shelton J; Harrison I
Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
[TBL] [Abstract][Full Text] [Related]
25. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
Casals-Stenzel J; Schmalbach J; Losert W
Eur J Clin Pharmacol; 1977 Dec; 12(4):247-55. PubMed ID: 590311
[TBL] [Abstract][Full Text] [Related]
26. SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone.
Cutler GB; Sauer MA; Loriaux DL
J Pharmacol Exp Ther; 1979 Apr; 209(1):144-6. PubMed ID: 430374
[TBL] [Abstract][Full Text] [Related]
27. Renal inactivation, mineralocorticoid generation, and 11beta-hydroxysteroid dehydrogenase inhibition ameliorate the antimineralocorticoid effect of progesterone in vivo.
Quinkler M; Meyer B; Oelkers W; Diederich S
J Clin Endocrinol Metab; 2003 Aug; 88(8):3767-72. PubMed ID: 12915667
[TBL] [Abstract][Full Text] [Related]
28. Effect of spironolactone on electrolytes, renin, ACTH and corticosteroids in the rat.
Chabert PR; Guelpa-Decorzant C; Riondel AM; Vallotton MB
J Steroid Biochem; 1984 Jun; 20(6A):1253-9. PubMed ID: 6087026
[TBL] [Abstract][Full Text] [Related]
29. Effect of spironolactone on the renin-aldosterone system in rats.
Jiménez W; Martínez-Pardo A; Arroyo V; Gaya J; Rivera F
Rev Esp Fisiol; 1988 Sep; 44(3):257-63. PubMed ID: 3068736
[TBL] [Abstract][Full Text] [Related]
30. Adaptation to chronic potassium loading in normal man.
Hené RJ; Koomans HA; Boer P; Dorhout Mees EJ
Miner Electrolyte Metab; 1986; 12(3):165-72. PubMed ID: 3523191
[TBL] [Abstract][Full Text] [Related]
31. Canrenone--the principal active metabolite of spironolactone?
Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
[TBL] [Abstract][Full Text] [Related]
32. Corticosteroid regulation of Na+ and K+ transport in the rat distal colon during postnatal development.
Pácha J; Popp M; Capek K
J Dev Physiol; 1988 Dec; 10(6):531-40. PubMed ID: 3246545
[TBL] [Abstract][Full Text] [Related]
33. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure.
van den Berg DT; de Kloet ER; van Dijken HH; de Jong W
Endocrinology; 1990 Jan; 126(1):118-24. PubMed ID: 2293978
[TBL] [Abstract][Full Text] [Related]
34. Endocrinological studies with desogestrel.
van der Vies J; de Visser J
Arzneimittelforschung; 1983; 33(2):231-6. PubMed ID: 6221730
[TBL] [Abstract][Full Text] [Related]
35. Mineralocorticoid like effect of new 18-hydroxy-steroid isolated from urine of hypertensive patients.
Palem-Vliers M; Fontaine F; Genard P
Endocrinol Exp; 1976 Mar; 10(1):59-63. PubMed ID: 1083802
[TBL] [Abstract][Full Text] [Related]
36. New mineralocorticoids: 5alpha-dihydroaldosterone and 5alpha-dihydro-11-deoxycorticosterone.
Sekihara H; Island DP; Liddle GW
Endocrinology; 1978 Oct; 103(4):1450-2. PubMed ID: 744157
[TBL] [Abstract][Full Text] [Related]
37. Sodium-retaining activity of some natural and synthetic 21-deoxysteroids.
Burton G; Galigniana M; De Lavallaz S; Brachet-Cota AL; Sproviero EM; Ghini AA; Lantos CP; Damasco MC
Mol Pharmacol; 1995 Mar; 47(3):535-43. PubMed ID: 7700251
[TBL] [Abstract][Full Text] [Related]
38. Mineralocorticoid and hypertensive effects of 19-nor-progesterone.
Hall CE; Gomez-Sanchez CE; Hungerford S; Gomez-Sanchez EP
Endocrinology; 1981 Oct; 109(4):1168-75. PubMed ID: 7285865
[TBL] [Abstract][Full Text] [Related]
39. Further studies on a new bioassay of progestational activity (traumatic deciduoma formation in immature rats).
Madjerek ZS; Smit-Vis JH
Acta Morphol Neerl Scand; 1977 Feb; 15(1):65-74. PubMed ID: 72488
[TBL] [Abstract][Full Text] [Related]
40. [Progestagens in contraception].
Kuhl H
Wien Med Wochenschr; 1987 Oct; 137(18-19):433-40. PubMed ID: 3318155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
